Research progress of Faricimab in the treatment of macular edema associated with retinal vascular diseases
10.3980/j.issn.1672-5123.2025.8.10
- VernacularTitle:Faricimab治疗视网膜血管疾病相关黄斑水肿的研究进展
- Author:
Xinyi HOU
1
;
Haoran WANG
1
;
Chunhua DAI
1
;
Jing ZHANG
1
;
Meng XIN
1
;
Zhixin GUAN
1
;
Shu LIU
1
Author Information
1. Second Clinical Medical University, Binzhou Medical University, Yantai 264100, Shandong Province, China
- Publication Type:Journal Article
- Keywords:
Faricimab;
diabetic macular edema;
retinal vein occlusion;
refractory macular edema;
bispecific antibody
- From:
International Eye Science
2025;25(8):1267-1273
- CountryChina
- Language:Chinese
-
Abstract:
Intravitreal injection of anti-vascular endothelial growth factor(VEGF)agents has become the primary treatment for macular edema associated with retinal vascular disease such as diabetic retinopathy and retinal vein occlusion, but there are limitations such as variable treatment efficacy and insufficient durability of therapeutic effects. As the first bispecific antibody applied in ophthalmic treatment, Faricimab achieves favorable outcomes by simultaneously targeting both VEGF-A and angiopoietin-2(Ang-2)pathways. Based on evidence from recent clinical trials and real-world studies, this article reviews the research progress on Faricimab for the treatment of diabetic macular edema(DME), retinal vein occlusion-associated macular edema(RVO-ME)and refractory macular edema compared to the therapeutic effects of other agents. Additionally, based on Faricimab's safety characteristics and future potential, its therapeutic prospects for macular edema associated with retinal vascular diseases are discussed. This review aims to provide evidence-based references for optimizing clinical treatment strategies, thereby contributing to mitigating the risk of vision loss due to macular edema.
